TG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
22 Settembre 2023 - 1:30PM
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael
S. Weiss, the Company’s Chairman and Chief Executive Officer, will
participate in the 2023 Cantor Global Healthcare Conference, being
held at the Intercontinental Barclay Hotel, in New York City on
September 26 - 28, 2023. The fireside chat is scheduled to take
place on Tuesday, September 26, 2023, at 12:25 PM ET.
A live webcast of the fireside chat will be available on the
Events page, located within the Investors & Media section, of
the Company’s website at http://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICSTG Therapeutics is a
fully integrated, commercial stage, biopharmaceutical company
focused on the acquisition, development and commercialization of
novel treatments for B-cell diseases. In addition to a research
pipeline including several investigational medicines, TG has
received approval from the U.S. FDA for BRIUMVI®
(ublituximab-xiiy), for the treatment of adult patients with
relapsing forms of multiple sclerosis, to include clinically
isolated syndrome, relapsing-remitting disease, and active
secondary progressive disease, as well as European Commission (EC)
approval for BRIUMVI to treat adult patients with RMS who have
active disease defined by clinical or imaging features. For more
information, visit www.tgtherapeutics.com, and follow us on
Twitter @TGTherapeutics and on LinkedIn.CONTACT:
|
Investor Relations |
|
Email: ir@tgtxinc.com |
|
Telephone: 1.877.575.TGTX (8489), Option 4 |
|
|
|
Media Relations: |
|
Email: media@tgtxinc.com |
|
Telephone: 1.877.575.TGTX (8489), Option 6 |
Grafico Azioni TG Therapeutics (NASDAQ:TGTX)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni TG Therapeutics (NASDAQ:TGTX)
Storico
Da Giu 2023 a Giu 2024